Does the FDA speed or slow innovation?

Neil Flanzraich • MARCH 20, 2016

Neil Flanzraich of Cantex Pharmaceuticals, Inc., outlines the various approaches that the U.S. Food and Drug Administration (FDA) uses to review new drug applications. He describes how the standards for approval have changed over the years, and what that means for pharmaceutical companies. For example, in order to quicken access to promising new therapies, accelerated review is now possible, provided that protocols are in place for post-market surveillance. In Flanzraich's view, some accommodations, such as the Breakthrough Product Designation, benefit drug companies differentially, with larger firms being much more able to demonstrate effectiveness in early clinical trials.

This video is from the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Visit the original source.
If the video on this page is broken, please report it.
This page has been viewed 872 times.

"I needed to know who the thought leaders were on a particular policy issue. A quick search through saved me hours!"

— Chris K., Palo Alto, CA